SLP Overview

Key Data

  • Open $44.96
  • Day Range 44.45 - 47.35
  • 52 Week Range 44.45 - 90.92
  • Market Cap $1.07B
  • Shares Outstanding 20.12M
  • Public Float 15.59M
  • Beta 0.80
  • Rev. per Employee $303.57K
  • P/E Ratio 80.63
  • EPS $0.57
  • Yield 0.52%
  • Dividend $0.06
  • Ex-Dividend Date Apr 23, 2021
  • Short Interest 2.44M 06/30/21
  • % of Float Shorted 15.67%
  • Average Volume 166.89K

Performance

5 Day
  • -15.79%
1 Month
  • -15.54%
3 Month
  • -24.76%
YTD
  • -36.23%
1 Year
  • -26.39%

Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 3 Full Ratings

Recent News

  • MarketWatch
  • Dow Jones

Simulations Plus Shares Down After Revenue Miss

Simulations Plus stock price target cut to $54 from $95 at Raymond James

Simulations Plus started at outperform with $95 stock price target at Raymond James

Simulations Plus started at outperform with $79 stock price target at Oppenheimer

Wednesday’s top gaining and declining stocks

A123 Systems, Kit Digital, Scotts Miracle-Gro

  • Other News
  • Press Releases

Simulations Plus, inc (SLP) Q3 2021 Earnings Call Transcript

on Motley Fool

Simulations Plus (SLP) to Post Q3 Earnings: What's in Store?

on Zacks.com

Simulations Plus (SLP) to Post Q3 Earnings: What's in Store?

on Zacks.com

Earnings Preview: Simulations Plus (SLP) Q3 Earnings Expected to Decline

on Zacks.com

Simulations Plus (SLP) Q2 Earnings & Revenues Top Estimates

on Zacks.com

Analysts Offer Insights on Technology Companies: Simulations Plus (SLP) and Atlassian (TEAM)

on SmarterAnalyst

Simulations Plus Inc (SLP) Q2 2021 Earnings Call Transcript

on Motley Fool

Simulations Plus (SLP) Q2 Earnings and Revenues Surpass Estimates

on Zacks.com

Simulations Plus (SLP) to Post Q2 Earnings: What to Expect?

on Zacks.com

Oppenheimer Issues a Buy Rating on Simulations Plus (SLP)

on SmarterAnalyst

Simulations Plus (SLP) Stock Down Despite Q1 Earnings Beat

on Zacks.com

Simulations Plus (SLP) Q1 Earnings and Revenues Top Estimates

on Zacks.com

Simulations Plus (SLP) to Post Q1 Earnings: What's in Store?

on Zacks.com

3 Skyrocketed Software Stocks That Might Lose Sheen in 2021

on Zacks.com

Simulations Plus (SLP) Q4 Earnings Flat Y/Y, Revenues Beat

on Zacks.com

Simulations Plus (SLP) Q4 Earnings and Revenues Surpass Estimates

on Zacks.com

Analysts Estimate Simulations Plus (SLP) to Report a Decline in Earnings: What to Look Out for

on Zacks.com

ORCL vs. SLP: Which Stock Should Value Investors Buy Now?

on Zacks.com

4 GARP Stocks to Scoop Up for Maximum Returns

on Zacks.com

Simulations Plus (SLP) Q3 Earnings & Revenues Beat Estimates

on Zacks.com

Simulations Plus Inc.

Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. It operates through the following segments: Simulations Plus, Inc., Cognigen Corporation, DILIsym, and Lixoft. It designs and develops pharmaceutical simulation software to promote cost-effective solutions to a number of problems in pharmaceutical research and in the education of pharmacy and medical students. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Lancaster, CA.

Competitors

Name Chg % Market Cap
Allscripts Healthcare Solutions Inc. -1.69% $2.59B
Competitor Data Provided ByCapital Cube Logo